Mineralys Therapeutics (MLYS) Set to Announce Quarterly Earnings on Tuesday

Mineralys Therapeutics (NASDAQ:MLYS) will announce its earnings results after the market closes on Tuesday, August 13th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.02). On average, analysts expect Mineralys Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS traded up $0.03 during trading hours on Tuesday, hitting $11.19. 81,063 shares of the company were exchanged, compared to its average volume of 181,685. The company’s 50 day moving average price is $12.74 and its 200-day moving average price is $12.90. The stock has a market capitalization of $555.58 million, a price-to-earnings ratio of -5.08 and a beta of 1.93. Mineralys Therapeutics has a 52-week low of $5.85 and a 52-week high of $16.91.

Insiders Place Their Bets

In related news, CFO Adam Scott Levy sold 96,815 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $12.94, for a total value of $1,252,786.10. Following the completion of the sale, the chief financial officer now owns 255,462 shares of the company’s stock, valued at $3,305,678.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Adam Scott Levy sold 96,815 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $12.94, for a total value of $1,252,786.10. Following the sale, the chief financial officer now owns 255,462 shares of the company’s stock, valued at $3,305,678.28. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 16,607 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $12.77, for a total transaction of $212,071.39. Following the sale, the chief executive officer now directly owns 1,032,461 shares in the company, valued at approximately $13,184,526.97. The disclosure for this sale can be found here. Insiders have sold a total of 706,779 shares of company stock valued at $9,206,318 in the last 90 days. 33.24% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, HC Wainwright initiated coverage on shares of Mineralys Therapeutics in a research report on Wednesday, July 10th. They set a “buy” rating and a $30.00 price target on the stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.